Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE versus METHADOSE.
HYDROCODONE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of pain.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Clinical Note
moderateHydrocodone + Torasemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide."
Clinical Note
moderateHydrocodone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid."
Clinical Note
moderateHydrocodone + Furosemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide."
Clinical Note
moderateHydrocodone + Bumetanide
Terminal elimination half-life is approximately 3.8-4.5 hours in adults; may be prolonged in hepatic or renal impairment.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal (67%) as conjugated morphine and normorphine, norhydrocodone, and hydromorphone; fecal (negligible).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide."